Public health impact of neovascular age-related macular degeneration treatments extrapolated from visual acuity

Investigative Ophthalmology and Visual Science

Volumn 48, Issue 1, 2007, Pages 96-103

  Bandello, Francesco ^a   Lafuma, Antoine ^b   Berdeaux, Gilles ^c,d  

^a UNIVERSITY OF UDINE   (Italy)

^b CEMKA EVAL   (France)

^c Alcon France ^*  (France)

^d Bioinformatique et Chimie Moléculaire   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BLINDNESS; COMORBIDITY; DEPRESSION; DISEASE SEVERITY; HIP FRACTURE; HUMAN; INSTITUTIONALIZATION; LIFE EXPECTANCY; MONOCULAR VISION; MORTALITY; OUTCOMES RESEARCH; PRIORITY JOURNAL; RETINA MACULA AGE RELATED DEGENERATION; SIMULATION; VISUAL ACUITY; VISUAL DISORDER; AGED; DISEASE COURSE; HEALTH STATUS; PATHOPHYSIOLOGY; PHYSIOLOGY; PROBABILITY; PUBLIC HEALTH; QUALITY OF LIFE; RETINA MACULA DEGENERATION; SUBRETINAL NEOVASCULARIZATION;

AGED; BLINDNESS; CHOROIDAL NEOVASCULARIZATION; DISEASE PROGRESSION; HEALTH STATUS; HUMANS; LIFE EXPECTANCY; MACULAR DEGENERATION; MARKOV CHAINS; PUBLIC HEALTH; QUALITY OF LIFE; VISION, LOW; VISUAL ACUITY;

EID: 33846895034     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: 10.1167/iovs.06-0283     Document Type: Article

References (44)

1. Leibowitz HM, Krueger DE, Maunder LR, et al. The Framingham Eye Study monograph: an ophthalmological and epidemiological study of cataract, glaucoma, diabetic retinopathy, macular degeneration, and visual acuity in a general population of 2631 adults, 1973-1975. Surv Ophthalmol. 1980;24:335-610.
2. Rosenberg T, Klie F. The incidence of registered blindness caused by age-related macular degeneration. Acta Ophthalmol Scand. 1996;74:399-402.
3. Fine SL, Berger JW, Maguire MG, Allen C. Age-related macular degeneration. N Engl J Med. 2000;342:483-492.
4. Arnold JJ, Sarks SH. Age related macular degeneration. BMJ. 2000;321:741-744.
5. Royal National Institute for the Blind. Office of National Statistics mid-1996 population estimates, estimates for 1996 of visually impaired people (ie, registerable) and the number of people registered blind and partially sighted as at 31st March 1997 in the UK. Available from http://www.rnib.org.uk/ wesupply/fctsheet/authuk.html. Accessed March 2000.
6. Blinder KJ, Bradley S, Bressler NM, et al. Effect of lesion size, visual acuity, and lesion composition on visual acuity change with and without verteporfin therapy for choroidal neovascularization secondary to age related macular degeneration. TAP and VIP Report No. 1. Am J Ophthalmol. 2003;136:407-418.
7. Bressler NM. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials. TAP Report No. 2. Arch Ophthalmol. 2001;119:198-207.
8. Bressler NM, Arnold J, Benchaboune M, et al. Verteporfin therapy of subfoveal choroidal neovascularization in patients with age related macular degeneration: additional information regarding baseline lesion composition's impact on vision outcomes. TAP Report No. 3. Arch Ophthalmol. 2002;120:1443-1454.
9. Rubin GS, Bressler NM. Treatment of age-related macular with Photodynamic therapy (TAP) study group: effects of verteporfin therapy on contrast sensitivity - results from the Treatment of Age Related Macular Degeneration With Photodynamic Therapy (TAP) investigation. TAP Report No. 4. Retina. 2002;22:536-44.
10. Blumenkranz MS, Bressler NM, Bressler SB et al. Verteporfin therapy for subfoveal choroidal neovascularization in age related macular degeneration: three year results of an open label extension of 2 randomized clinical trials. TAP Report No. 5. Arch of Ophthalmol. 2002;120:1307-1314.
11. Barbazetto I, Burdan A, Bressler NM et al. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy Study Group; Verteporfin in Photodynamic Therapy Study Group. Photodynamic therapy of subfoveal choroidal neovascularization with verteporfin: fluorescein angiographic guidelines for evaluation and treatment. TAP and VIP Report No. 2. Arch Ophthalmol. 2003;121:1253-1268.
12. Gragoudas ES, Adamis AP, Cunningham ET, Feinsod M, Guyer DR. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med. 2004;351:2805-2816.
13. Meads C, Salas C, Roberts T, Moore D, Fry-Smith A, Hyde C. Clinical effectiveness and cost-utility of photodynamic therapy for wet age-related macular degeneration: a systematic review and economic evaluation. Health Technol Assess. 2003;7:1-98.
14. National Institute for Clinical Excellence. http://www.nice.org.uk/ docref.asp?d=87234/. Accessed August 2005.
15. PubMed. National Library of Medicine. Available at http://www.ncbi.nih. gov/entrez/query.fcgi/. Accessed December 2004.
16. Photodynamische Therapie mit Verteprofin bei altersabhängiger feuchter Makuladegeneration mit subfovealären klassischen choriodalen Neovaskularisationen. Zusammenfassender Bericht des Arbeitsausschusses "Árztliche Behandlung" des Bundesausschusses der Ártze und Krankenkassen über die Beratungen gemäss § 135 Abs. 1 SGB V.Geschäftsführung des Arbeitsausschusses. Koln, Germany, 2001.
17. Photodynamic treatment for macular degeneration. SBU. The Swedish Council on Technology Assessment in Health Care. Stockholm, Sweden, 2001. http://www.sbu.se/www/index.asp/. Accessed August 2005.
18. Journal officiel de la république Française. Arrêté du 13 Février 2001 modifiant la liste des spécialités pharmaceutiques remboursables aux assurés sociaux. Paris, Ed le Journal officiel. Le 22 Février 2001;2898-2900.
19. Legood R, Scuffham P, Cryer C. Are we blind to injuries in the visually impaired? - a review of the literature. Inj Prev. 2002;8:155-160.
20. Tsai SY, Cheng CY, Hsu WM, Su TP, Liu JH, Chou P. Association between visual impairment and depression in the elderly. J Formos Med Assoc. 2003;102:86-90.
21. Jongenelis K, Pot AM, Eisses AM, Beekman AT, Kluiter H, Ribbe MW. Prevalence and risk indicators of depression in elderly nursing home patients: the AGED study. J Affect Disord. 2004;83:135-142.
22. Lupsakko T, Mantyjarvi M, Kautiainen H, Sulkava R. Combined hearing and visual impairment and depression in a population aged 75 years and older. Int J Geriatr Psychiatry. 2002;17:808-813
23. Casten RJ, Rovner BW, Tasman W. Age-related macular degeneration and depression: a review of recent research. Curr Opin Ophthalmol. 2004;15:181-183.
24. Rovner BW, Casten RJ. Activity loss and depression in age-related macular degeneration. Am J Geriatr Psychiatry. 2002;10:305-310.
25. Brody BL, Gamst AC, Williams RA, et al. Depression, visual acuity, comorbidity, and disability associated with age-related macular degeneration. Ophthalmology. 2001;108:1893-1900.
26. Cacciatore F, Abete P, Maggi S, et al. Disability and 6-year mortality in elderly population: role of visual impairment. Aging Clin Exp Res. 2004;16:382-388.
27. Taylor HR, McCarty CA, Nanjan MB. Vision impairment predicts five-year mortality. Trans Am Ophthalmol Soc. 2000;98:91-96.
28. Thompson JR, Gibson JM, Jagger C. The association between visual impairment and mortality in elderly people. Age Ageing. 1989;18:83-88.
29. Lee DJ, Gómez-Marín O, Lam BL, Zheng DD. Visual impairment and unintentional injury mortality: The National Interview Survey. Am J Ophthalmol. 2003;136:1152-1154.
30. Lee DJ, Gómez-Marín O, Lam BL, Zheng DD. Visual acuity impairment and mortality in U.S. adults. Arch Ophthalmol. 2002;120:1544-1550.
31. McCarty CA, Nanjan MB, Taylor HR. Vision impairment predicts 5 year mortality. Br J Ophthalmol. 2001;85:322-326.
32. Berdeaux G, Brézin A, Fagnani F, Mesbah M, Lafuma A. Self-reported visual impairment and mortality: a French nationwide perspective. Ophthalmic Epidemiol. In press.
33. Brézin A, Lafuma A, Fagnani F, Mesbah M, Berdeaux G. Blindness, low vision and other handicaps as risk factors attached to institutional residence. Br J Ophthalmol. 2004;88:1330-1337.
34. Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Making. 1993;13:322-338.
35. Mukesh BN, Dimitrov PN, Leikin S, et al. Five-year incidence of age-related maculopathy: The Visual Impairment Project. Ophthalmology. 2004;111:1176-1182.
36. OECD - Organisation for Economic Co-operation and Development. OECD health data: A comparative analysis of 29 Countries. Credes Paris: Eco-Sante Software, Paris; 1999.
37. INSEE-Bulletin mensuel de statistique, no 1-2003.
38. Billotte C, Berdeaux G. Adverse clinical consequences of posterior capsular opacification treatment by Nd-Yag laser. J Cataract Refract Surg. 2004;30:2064-2071.
39. Galaria II, Casten RJ, Rovner BW. Development of a shorter version of the geriatric depression scale for visually impaired older patients. Int Psychogeriatr. 2000;12:435-443.
40. Dargen-Molina P, Douchin MN, Cormier C et al Use of clinical risk factors in elderly women with low bone mineral density to identify women at higher risk of hip fracture: the EPIDOS prospective study. Osteoporosis Int. 2002;13:593-599-
41. Elffors I, Allander E, Kanis JA et al. The variable incidence of hip fracture in southern Europe: the MEDOS Study. Osteopors Int. 1994;4:253-263.
42. Bouyer J, Hémon D, Cordier S et al. Epidémiologie, principes et methods quantitatives. 1993 Les editions INSERM.
43. D'Amico DJ, Goldberg MF, Hudson H, et al. Anecortave acetate as monotherapy for treatment of subfoveal neovascularization in age-related macular degeneration: twelve-month clinical outcomes. Ophthalmology. 2003;110:2372-2383.
44. Lafuma AJ, Brezin AP, Fagnani FL, Mesbah M, Berdeaux GH. Prevalence of visual impairment in relation to the number of ophthalmologists in a given area: a nationwide approach. Health Qual Life Outcomes. 2006;4:34.